Analysis of the association between cetp taq1B polymorphism (rs708272) and cholesterol lowering effects among statin users with hyperlipidaemia from HUSM : a pilot study
Statin, a cholesterol lowering agent, is widely used for treatment of hyperlipidemia (HPL) nowadays. Generally, statin is effective in reducing cholesterol level. However, there is a marked inter-patient variation with regard to response to statin treatment possibly due to differences in patients...
Saved in:
| Main Author: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
2018
|
| Subjects: | |
| Online Access: | http://eprints.usm.my/45922/1/Dr.%20Ilani%20Ab%20Rahman-24%20pages.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Statin, a cholesterol lowering agent, is widely used for treatment of hyperlipidemia (HPL)
nowadays. Generally, statin is effective in reducing cholesterol level. However, there is a
marked inter-patient variation with regard to response to statin treatment possibly due to
differences in patients’ genetic makeup, their demographic profiles, and other clinical factors.
A single nucleotide polymorphism(SNP) in Cholesteryl Ester Transfer Protein (CETP) Taq1B
(rs708272) gene was reported as a promising predictive genetic marker for cholesterol lowering
effect in many populations Until now, there is no genetic association study among Malaysian
population has been explored the influence of the particular SNP on statin’s cholesterol
lowering effects. Hence, we aim to study the association of CETP Taq1B (rs708272) variants
together with other clinical factors on cholesterol lowering effect of statin among HPL patients
from Hospital Universiti Sains Malaysia (HUSM), Kelantan. This is a retrospective study
which involves 81 HPL patients. The details regarding demographic and clinical characteristics
of patients were obtained via interview and patient’s medical record. The genotyping of DNA
samples of HPL patients were performed by using Polymerase Chain Reaction-Restriction
Fragment Length Polymorphism (PCR-RFLP). The results indicate that there were no
significant association between patients’ demographic profiles as well as clinical factors and
their statin cholesterol lowering effects. Interestingly, variant in CETP Taq1B rs708272 has
been associated with statin’s cholesterol lowering effects for a certain degree. In homozygousmutant patient with B2B2 (AA) genotype has higher HDL-C level (P<0.05) than other
genotypes (1.39±0.33 vs 1.29±0.32 and 1.26±0.29). The LDL-C and TC level were decreased
significantly (P<0.01) in heterozygous variant patient with B1B2 (AG) genotype. While TG
level was decreased significantly in B1 carrier. This finding warrants further multicenter
investigation to confirm the association of the SNP with regards to the statin effectiveness on
both LDL-C and HDL-C profile. |
|---|